Cortexyme company info

What does Cortexyme do?
Quince Therapeutics (NASDAQ:QNCX) is a late-stage biotech company developing innovative treatments for rare diseases. Their lead asset, EryDex, utilizes a unique technology platform to encapsulate a drug within a patient's red blood cells. This approach targets Ataxia-Telangiectasia (A-T), a debilitating childhood disease with no current cure. EryDex is expected to enter pivotal Phase 3 trials in Q2 2024. Quince's AIDE technology is flexible and holds promise for future applications beyond A-T.
Cortexyme company media
Company Snapshot

Is Cortexyme a public or private company?

key
Ownership
Public

How many people does Cortexyme employ?

people
Employees
32

What sector is Cortexyme in?

pie chart
Sector
Health Care

Where is the head office for Cortexyme?

location pin
Head Office
South San Francisco, United States

What year was Cortexyme founded?

founded flag
Year Founded
2012
What does Cortexyme specialise in?
/Alzheimer's Treatment /Research Biotech /Clinical Trials /Drug Development /Neurodegenerative Diseases /Pharmaceutical Products

What are the products and/or services of Cortexyme?

Overview of Cortexyme offerings
Drug Delivery Technology Development: Quince Therapeutics focuses on perfecting their AIDE (Autologous In-vivo Delivery Engine) platform. This technology involves engineering a patient's red blood cells to encapsulate therapeutic drugs.
Drug Candidate Development: Quince utilizes their AIDE platform to develop targeted therapies for specific diseases. Their lead candidate, EryDex, focuses on treating Ataxia-Telangiectasia (A-T).
Pre-Clinical and Clinical Research: Quince conducts pre-clinical studies in labs to assess the safety and efficacy of their drug candidates. They also design and manage clinical trials to test their drug candidates in human subjects.
Regulatory Affairs: Quince interacts with regulatory agencies like the FDA to obtain approval for their technology platform and potential drug therapies.
Manufacturing Development: If their drug candidates receive regulatory approval, Quince will need to establish processes for large-scale manufacturing to make their treatments available to patients.
Partnerships and Collaborations: Quince may collaborate with other pharmaceutical companies or research institutions to leverage expertise or resources for further development or commercialization of their technologies.

Who is in the executive team of Cortexyme?

Cortexyme leadership team
  • Dr. Dirk  Thye M.D.
    Dr. Dirk Thye M.D.
    CEO & Director
  • Mr. Brendan  Hannah M.B.A.
    Mr. Brendan Hannah M.B.A.
    Principal Financial Officer, Principal Accounting Officer, Chief Business Officer & COO
  • Dr. Charles S. Ryan J.D., Ph.D.
    Dr. Charles S. Ryan J.D., Ph.D.
    President
  • Dr. Guenter R. Janhofer M.D., Ph.D.
    Dr. Guenter R. Janhofer M.D., Ph.D.
    Chief Scientific Officer
  • Ms. Stacy  Roughan
    Ms. Stacy Roughan
    Vice President of Corporate Communications & Investor Relations
  • Ms. Mary Ellen Sillivos
    Ms. Mary Ellen Sillivos
    Vice President of Human Resources
  • Dr. Stewart A. Low Ph.D.
    Dr. Stewart A. Low Ph.D.
    Head of Discovery